Isicom Retard

Levodopa/Carbidopa, the active ingredient in Isicom Retard, is a Levodopa/Carbidopa combination presented as a standard strength tablet for oral use. It helps restore dopamine levels in the brain, thereby reducing motor symptoms of Parkinson's disease in adult patients.

GNH USA supplies Isicom Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across all markets. Our distribution network adheres to stringent quality standards and provides reliable delivery to healthcare providers across Europe, Asia and the Americas.

Isicom Retard, a Levodopa/Carbidopa combination, is used within the Parkinson's disease therapeutic pathway to improve motor function.

- Parkinson's disease: alleviates bradykinesia, rigidity and tremor in patients with idiopathic Parkinson's disease. - Parkinsonian syndrome: improves motor symptoms caused by drug‑induced or vascular Parkinsonism. - Levodopa‑responsive dystonia: reduces abnormal muscle contractions in patients with dopa‑responsive dystonic disorders.

Levodopa/Carbidopa therapy may be associated with a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Insomnia: difficulty initiating or maintaining sleep. - Dyskinesia: involuntary, erratic movements. - Dry mouth: reduced salivation. - Constipation: slowed bowel motility.

Serious or Rare Side Effects: - Psychosis: hallucinations or delusional thinking. - Severe hypotension: marked blood pressure drop requiring medical attention. - Cardiac arrhythmias: irregular heart rhythms. - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hyperpyrexia: unusually high body temperature.

When prescribing Isicom Retard, clinicians should consider several safety measures.

- Monitor blood pressure: watch for orthostatic changes, especially after dose initiation. - Assess for dyskinesia: adjust dose if involuntary movements develop. - Evaluate psychiatric status: be alert for hallucinations or mood changes. - Adjust dose in renal impairment: consider reduced clearance in patients with kidney dysfunction. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal symptoms. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levodopa/Carbidopa may interact with several other medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may diminish antiparkinsonian effect. - High‑dose pyridoxine (vitamin B6): can increase peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - MAO‑B inhibitors (e.g., selegiline): may potentiate dopaminergic effects. - Anticholinergics: may increase risk of confusion in elderly. - Iron supplements: can reduce levodopa absorption; separate dosing by at least 2 hours.